Background Cardiovascular complications; myocardial infarction (MI), ischemic stroke, and
pulmonary embolism (PE), represent an important source of adverse outcomes in COVID-19 …

Background: Many studies have evaluated thromboembolic events in COVID-19 patients,
and most of them have reported a high estimation of the prevalence of such events. The …

Background Cardiovascular complications, including myocardial infarction, ischemic stroke,
and pulmonary embolism, represent an important source of adverse outcomes in …

Background Few data are available on the rate and characteristics of thromboembolic
complications in hospitalized patients with COVID-19. Methods We studied consecutive …

Introduction COVID-19 may predispose to both venous and arterial thromboembolism due to
excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation …

Background We aimed to identify the prevalence and predictors of venous
thromboembolism (VTE) or mortality in hospitalized coronavirus disease 2019 (COVID-19) …

Background Thromboembolism is the third most common cardiovascular disorders and
substantial worldwide health burden, with 1–2 instances per 1000 persons each year. This …

Introduction The incidence of thromboembolism during COVID-19 and the use of
thromboprophylaxis vary greatly between studies. Only a few studies have investigated the …

Background The coronavirus disease 2019 (COVID‐19) is a newly recognized illness that
has spread rapidly all over the world. More and more reports highlight the risk of venous …

Methods We retrospectively reviewed the records of 4014 consecutive adult patients
admitted to a tertiary-level institution because of COVID-19 from March 2020 to March 2021 …